Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist.
Cosi C, Martel JC, Auclair AL, Collo G, Cavalleri L, Heusler P, Leriche L, Gaudoux F, Sokoloff P, Moser PC, Gatti-McArthur S. Cosi C, et al. Among authors: gaudoux f. Eur J Pharmacol. 2021 Jan 5;890:173635. doi: 10.1016/j.ejphar.2020.173635. Epub 2020 Oct 14. Eur J Pharmacol. 2021. PMID: 33065094
Cognitive Impairment and Diminished Neural Responses Constitute a Biomarker Signature of Negative Symptoms in Psychosis.
Hudgens-Haney ME, Clementz BA, Ivleva EI, Keshavan MS, Pearlson GD, Gershon ES, Keedy SK, Sweeney JA, Gaudoux F, Bunouf P, Canolle B, Tonner F, Gatti-McArthur S, Tamminga CA. Hudgens-Haney ME, et al. Among authors: gaudoux f. Schizophr Bull. 2020 Sep 21;46(5):1269-1281. doi: 10.1093/schbul/sbaa001. Schizophr Bull. 2020. PMID: 32043133 Free PMC article.
Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11C]-(+)-PHNO.
Slifstein M, Abi-Dargham A, Girgis RR, Suckow RF, Cooper TB, Divgi CR, Sokoloff P, Leriche L, Carberry P, Oya S, Joseph SK, Guiraud M, Montagne A, Brunner V, Gaudoux F, Tonner F. Slifstein M, et al. Among authors: gaudoux f. Psychopharmacology (Berl). 2020 Feb;237(2):519-527. doi: 10.1007/s00213-019-05387-w. Epub 2019 Nov 26. Psychopharmacology (Berl). 2020. PMID: 31773210 Clinical Trial.
Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia.
Bitter I, Lieberman JA, Gaudoux F, Sokoloff P, Groc M, Chavda R, Delsol C, Barthe L, Brunner V, Fabre C, Fagard M, Montagne A, Tonner F. Bitter I, et al. Among authors: gaudoux f. Neuropsychopharmacology. 2019 Oct;44(11):1917-1924. doi: 10.1038/s41386-019-0355-2. Epub 2019 Mar 1. Neuropsychopharmacology. 2019. PMID: 30822774 Free PMC article. Clinical Trial.
11 results